New Insights into Uveitis in Spondyloarthritis

Save

Uveitis is the most frequent extra-musculoskeletal manifestation (EAM) in Axial Spondyloarthritis (axSpA). The prevalence of uveitis in axSpA is between 25-30%. Up to 50% of patients with an acute episode of uveitis develop recurrent anterior uveitis or iritis.

ACR21 Best Abstracts We Saw - Day 3 (Monday)

Save

The third day of ACR 2021 took a big leap in online content.  Here is a compilation (with links) of presentations were the “ACRBest” as seen by our RheumNow faculty. 

Day 2 Report from ACR21

Save

This report highlights the VITAL trial; the ORAL Surveillance Study; and the Microbiome study of monozygotic psoriasis patients.

Axial spondyloarthritis with psoriasis or psoriatic spondylitis

Save

PsA commonly affects peripheral joints. In up to a quarter of PsA patients, the spine may be involved and this is known as psoriatic spondylitis (PsSpA). An important research question is whether PsSpA and Axial Spondyloarthritis (AxSpA) with psoriasis are separate conditions or not. 

Infection or Disease Flare: What Tools Can Help Differentiate?

Save

Differentiation between a flare of disease and infection in patients with autoinflammatory (AI) conditions, where fever is the hallmark, can be extremely difficult. Few studies have evaluated potential differentiators; and having such tools would meet a huge unmet need. 

Methotrexate and hepatic fibrosis: we must be doing something right

Save

Methotrexate may be a rheumatologist’s best friend, but a key part of counselling any patient about its use has always been the risk of hepatotoxicity.

Can tender and swollen joint counts work in a telemedicine world?

Save

In a world where telemedicine and virtual care are not going away, is there value in patients assessing their own tender and swollen joints?

After failing a JAK inhibitor, can you still hit a JAK-pot?

Save

Januse kinase (JAK) inhibitors are targeted synthetic disease modifying anti-rheumatic drugs (tsDMARDs) that have risen in popularity as earlier treatment options for rheumatoid arthritis.

ACR21 Best Abstracts - Day 2

Save

The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest).

Day 1 Report from ACR21

Save

The first full day of Abstracts and Presentations from ACR Convergence, was full of highly engaging sessions, quality posters and unique presentations. To hear more about the best of the best, I would encourage you to look at our Day 1 Recap Video and Day 1 ACR Best Abstracts. Here are a few of my favorites from the first day.

TNF inhibitors and radiographic progression in axSpA

Save

A remaining challenge for clinicians is the ability to delay, if not completely stop, structural progression in patients with axSpA, whether they are diagnosed with radiographic (r-axSpa) or non-radiographic (nr-axSpA) disease.

JAK Inhibitors in Refractory Adult and Childhood-Onset Still’s Disease

Save

Still's disease is an autoinflammatory disease characterized by spiking fever, rash, polyarthralgia, sore throat and even life-threatening complications, such as macrophage activation syndrome. It was first described by George Still in the late 1800s.